CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) Director Brian Guan-Chyun Liu acquired 371,085 shares of CG Oncology stock in a transaction dated Thursday, June 25th. The shares were bought at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the transaction, the director owned 1,886,236 shares of the company’s stock, valued at approximately $126,132,601.32. The trade was a 24.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
CG Oncology Stock Performance
Shares of NASDAQ CGON opened at $71.05 on Wednesday. The company has a market cap of $6.27 billion, a P/E ratio of -30.49 and a beta of 0.31. The firm’s fifty day moving average is $64.50 and its two-hundred day moving average is $58.54. CG Oncology, Inc. has a 52-week low of $23.65 and a 52-week high of $77.00.
CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The business had revenue of $1.08 million for the quarter, compared to analyst estimates of $0.45 million. As a group, analysts forecast that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.
Analyst Ratings Changes
View Our Latest Stock Report on CGON
Hedge Funds Weigh In On CG Oncology
A number of large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in CG Oncology by 321.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock valued at $9,179,000 after buying an additional 173,785 shares during the period. Vanguard Group Inc. increased its position in shares of CG Oncology by 11.4% during the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock worth $264,933,000 after acquiring an additional 670,770 shares during the period. Mangrove Partners IM LLC increased its position in shares of CG Oncology by 21.0% during the third quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock worth $27,056,000 after acquiring an additional 116,575 shares during the period. Sivik Global Healthcare LLC bought a new stake in shares of CG Oncology during the fourth quarter valued at approximately $1,453,000. Finally, HighVista Strategies LLC raised its stake in shares of CG Oncology by 152.1% during the third quarter. HighVista Strategies LLC now owns 26,040 shares of the company’s stock valued at $1,049,000 after acquiring an additional 15,712 shares in the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.
CG Oncology Company Profile
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Featured Stories
- Five stocks we like better than CG Oncology
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
